Understanding the biology of EGFR signaling, which by then had also been resolved in mammalian cells, allowed the identification of KRAS activating mutations as primary responsible for intrinsic resistance to anti‐EGFR treatment in CRC [7, 8]. The gene discussed is EGFR; the disease is colorectal carcinoma.